Protonix (Pantoprazole Sodium) Patent Expiration, LOE Window & CMS Spending

Protonix (Pantoprazole Sodium) by Pfizer: FDA Orange Book LOE 2026-12-07, 19 AB generics, $15.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN020987 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-12-07
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors19
2024 CMS Total Public Spend$15.7M
2024 Medicare Part D Spend$10.7M
2024 Medicaid Spend$5.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.